Rohit Malde

Radiosensitising strategies in locally advanced head and neck cancer: a systematic review and network meta-analysis of randomised controlled trials
RADIANCE-NMA (2026)
N=13768 pts across 67 trials
[1977-2025]

Platinum = winner

KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II NSCLC

N=448
SBRT 45–60 Gy / 3 fractions
Pembrolizumab 200 mg IV every 3 weeks x 17 cycles.

Primary End Point fails
EFS HR=0.92 p=0.2932

Long-Term Outcomes of De-Escalated 30-Gy Elective Irradiation in HPV-Associated Oropharyngeal Cancer.

MSKCC Retrospective Data
DOI: 10.1001/jamaoncol.2026.4014.

N=276 [Mar17 to Sep19]
Median FU 64m
IMRT (256), IMPT (20)
Elective nodal volumes
30 Gy/15#
Primary +Inv Neck=70 Gy

Katherine Trial

Ph III trial

Early Breast Cancer Her2+

Neoadj Chemo → Surgery → Residual Disease → TDM1 3.6mg/kg) q3 weeks X 14 cycles [ Total 10 Months]

Trial at Glance with Mature 7y Efficacy outcomes and Toxicity

From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in HR+/HER2− Early Breast Cancer

DOI: 10.1200/JCO-26-01976⁠